Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Journal of Experimental Hematology ; (6): 1466-1469, 2016.
Article in Chinese | WPRIM | ID: wpr-332668

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the expression level of S100A6 mRNA in MM and to its clinical significance, and to evaluate its significance.</p><p><b>METHODS</b>The expression level of S100A6 mRNA in MM patients was determined by real time quantitative PCR(RQ-PCR), and its relationship with the clinical features and outcomes of patients was analyzed by statistic method.</p><p><b>RESULTS</b>S100A6 mRNA was detected in 20 MM patients. Compared with normal persons, the S100A6 mRNA expression in MM patients was higher. In different groups, the S100A6 mRNA expression in MM patients of 3 stages was higer than that in patients of 1 and 2 stages. MM patients with higher S100A6 mRNA expression had poor prognosis and higer extramedullary metastasis rate.</p><p><b>CONCLUSION</b>The high expression of S100A6 mRNA is associated with poor prognosis and may be a prognostic molecular marker of MM.</p>

2.
Journal of Experimental Hematology ; (6): 1640-1643, 2014.
Article in Chinese | WPRIM | ID: wpr-340444

ABSTRACT

This study was aimed to investigate the normalization of serum free light chain ratio (sPLCR) after treatment of multiple myeloma (MM) and its influence on the prognosis of MM patients. The clinical data of 42 patients with MM were analyzed retrospectively from January 2009 to November 2013 in out department. According to sPLCR consecutive normalization for more 4 weeks or not after treatment, the patients were classified in patients with mormalized sPLCR and patients with abnormalized sPLCR, then the influence of traditional prognostic factors of MM on sPLCR and effect of sPLCR on overall survival (OS) time of MM patients were analyzed. The results showed that the influence of age, ISS stage displayed statistical difference between sFLCR normalization group and abnormalization group, the age ≥ 65 years and ISS stage III negatively impacted on sFLCR normalization (P < 0.05). The response rates of patients with normalized sFLCR were as follows: CR - 60%, VGPR - 38.89%; PR - 28.57%; 17 patients (40.48%) with sFLCR normalization showed superior OS, as compared with patients with sPLCR abnormalization (P < 0.01). It is concluded that the sFLCR normalization is the independent prognostic factor for MM, suggesting that the MM patients with sPLCR normalization after treatment have superior prognosis.


Subject(s)
Aged , Humans , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Immunoglobulin Light Chains , Allergy and Immunology , Multiple Myeloma , Diagnosis , Drug Therapy , Allergy and Immunology , Prognosis , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL